Anish Patel Sells 716 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel sold 716 shares of the business’s stock in a transaction on Friday, October 18th. The shares were sold at an average price of $30.00, for a total value of $21,480.00. Following the completion of the transaction, the chief operating officer now owns 343,311 shares of the company’s stock, valued at $10,299,330. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Enliven Therapeutics Stock Down 0.0 %

NASDAQ:ELVN opened at $28.97 on Thursday. The company has a market cap of $1.36 billion, a P/E ratio of -15.01 and a beta of 1.10. The firm’s 50 day moving average is $24.52 and its two-hundred day moving average is $22.88. Enliven Therapeutics, Inc. has a fifty-two week low of $9.80 and a fifty-two week high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.17. Research analysts forecast that Enliven Therapeutics, Inc. will post -1.98 earnings per share for the current fiscal year.

Institutional Trading of Enliven Therapeutics

A number of institutional investors have recently modified their holdings of the company. SG Americas Securities LLC purchased a new position in Enliven Therapeutics in the third quarter valued at approximately $256,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Enliven Therapeutics in the second quarter worth $322,000. Marshall Wace LLP purchased a new position in shares of Enliven Therapeutics in the 2nd quarter valued at $4,489,000. First Turn Management LLC acquired a new position in shares of Enliven Therapeutics during the 2nd quarter valued at $9,657,000. Finally, Nicholas Investment Partners LP purchased a new stake in Enliven Therapeutics during the 2nd quarter worth $1,310,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $37.00 target price on shares of Enliven Therapeutics in a research note on Tuesday, October 1st.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.